Advances in the Treatment of Malignant Melanoma

Source: OncLive, June 2020

Jeffrey S. Weber, MD, PhD: Hello, and welcome to this OncLive® Peer Exchange® titled “Advances in the Treatment of Malignant Melanoma.” I’m Dr Jeffrey Weber. I’m from the Perlmutter Cancer Center at NYU Langone Health in New York, New York. Joining me today in this virtual discussion are my colleagues Dr Sunandana Chandra, who’s from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago, Illinois; Dr Adil Daud, who’s from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California; Dr Jason Luke, who’s from the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania; and Dr Ryan Sullivan, who’s from Massachusetts General Hospital Cancer Center in Boston, Massachusetts. Welcome.

Today we’re going to review the latest data on melanoma released from the 2020 ASCO [American Society of Clinical Oncology] Annual Meeting. Let’s get started on our first topic.

The first topic talks about perioperative approaches to melanoma. A question that we medical oncologists deal with is: What’s the optimal approach to the multidisciplinary management of locally advanced melanoma? Ryan, tell me, how do folks at your institution handle the multidisciplinary management of the disease?

READ THE ORIGINAL FULL ARTICLE